Introduction
Defining the success of BD's Veritor Plus System for rapid COVID-19 testing requires a comprehensive approach that considers multiple stakeholders and metrics. This product success metric framework will cover core metrics, supporting indicators, and risk factors while addressing the needs of healthcare providers, patients, and public health officials.
I'll follow a simple success metrics framework covering product context, success metrics hierarchy, and strategic initiatives.
Step 1
Product Context
The BD Veritor Plus System is a portable, rapid antigen test for detecting SARS-CoV-2. It's designed for point-of-care use, providing results in about 15 minutes. Key stakeholders include:
- Healthcare providers: Seeking quick, accurate diagnostics
- Patients: Needing timely results and minimal discomfort
- Public health officials: Tracking infection rates and managing outbreaks
- BD (Becton, Dickinson and Company): Aiming for market share and profitability
User flow:
- Sample collection: Healthcare worker swabs patient's nose
- Test preparation: Sample is mixed with reagent and applied to test device
- Analysis: Veritor Plus reader processes and interprets results
- Results delivery: Healthcare worker communicates outcome to patient
The Veritor Plus System fits into BD's broader strategy of expanding its diagnostic portfolio and addressing urgent public health needs. Compared to competitors like Abbott's ID NOW, the Veritor Plus offers similar speed but potentially lower sensitivity.
Product Lifecycle Stage: Growth - The product has gained traction but still has room for expansion and improvement in a rapidly evolving market.
Hardware considerations:
- Manufacturing scalability to meet demand surges
- Supply chain resilience for consistent availability
- Service infrastructure for maintenance and support
Practice similar questions
Subscribe to access the full answer
.png){kind=logo}
